Empagliflozin-d4
Product Specifications
UNSPSC Description
Empagliflozin-d4 is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2[1].
Target Antigen
SGLT
Type
Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Solubility
10 mM in DMSO
Smiles
ClC(C=CC([C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)=C2)=C2CC3=C(C([2H])=C(C([2H])=C3[2H])O[C@H]4CCOC4)[2H]
Molecular Weight
454.93
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Cheng ST, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PLoS One. 2016 Jan 25;11(1):e0147391.|[3]Grempler R, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012 Jan;14(1):83-90.|[4]Nikole J.ByrneBSc, et al. Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. JACC Basic Transl Sci. 2017 Aug;2(4):347-354.|[5]Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. Int J Med Sci. 2018 Jun 13;15(9):937-943.
Shipping Conditions
Room Temperature
Clinical Information
No Development Reported
CAS Number
2749293-95-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1029076-01 1 mg (E-Coli)
Recombinant Persephonella marina NADH-quinone oxidoreductase subunit N (nuoN), partial
Ask
View Details MBS1029076-02 1 mg (Yeast)
Recombinant Persephonella marina NADH-quinone oxidoreductase subunit N (nuoN), partial
Ask
View Details 